Author: admin

JollyLook’s DIY Instant Film Camera: Where Vintage Meets DIY Charm – Reviving Classic Photography With Sustainable Elegance

JollyLook’s DIY Instant Film Camera merges artistry, nostalgia, and innovation in a unique 3d puzzle experience that transcends time.

In a world where screens dominate our attention, JollyLook brings an exhilarating escape through the art of analog photography. Introducing the DIY Pinhole Instant Film Camera Kit—a delight for craft enthusiasts, hobbyists, and those enamored with retro charm. 

This unique kit isn’t just a camera; it’s a project, a puzzle, and a model all in one, promising an unforgettable bonding experience. Designed as a 3D puzzle for adults, it sparks nostalgia, inviting you to dive into the magic of the earliest cameras from 200 years ago.

“JollyLook is more than a product; it’s an experience,” says the company’s spokesperson. “It’s about rediscovering the joy of building, learning, and capturing moments in a tangible, hands-on way.”

Rediscovering Old-School Photography

Long before the era of DSLRs and digital cameras, the humble pinhole camera was the pioneer in capturing light. JollyLook revives this timeless art form with its DIY Pinhole Instant Film Camera Kit—a fusion of craftsmanship and photographic heritage.

A Great Way to Bond with Family and Friends 

The JollyLook instant film camera kit is not just an average puzzle. Beyond interlocking pieces, it invites enthusiasts to delve into the intricacies of camera mechanics. Assembling this 3D puzzle isn’t just a task; it’s an exploration of spatial understanding and a celebration of craftsmanship. With the holiday season just around the corner, assembling this mighty camera with friends and family might just be the perfect activity. It proves as an excellent gift since the finished project can be used to eternalize the memory of this shared bonding experience in the form of a photograph.  

Stimulating the Mind

The Jollylook camera has been carefully designed to keep users’ best interests in mind. Engaging with 3D wooden puzzles offers a multitude of benefits—enhancing spatial reasoning memory and providing a therapeutic escape from digital screens. Moreover, the sustainability and tactile warmth of wooden puzzles add a unique charm to the assembly process.

Similarly, the use of a pinhole camera strips away the complexities of modern photography, focusing on the basics of light and shadow. It fosters patience, an appreciation for light, and the sheer enchantment of capturing an image through a minuscule aperture.

Crafted with Precision and Eco-consciousness

Made from predominantly eco-friendly materials, the JollyLook camera exudes durability and rustic charm. The inclusion of a key as a pivotal tool in the assembly process adds to the allure and functionality of the camera.

Preserving Moments and Masterpieces

Once assembled, the JollyLook camera captures ethereal, dreamy images—a testament to the artistry of pinhole photography. As with any film, these images are to be preserved in a cool, dry place, while the camera itself stands as a timeless keepsake, a conversation starter, and a testament to craftsmanship.

Embark on a Journey of Creativity

Whether an avid photography enthusiast or someone captivated by the challenge of 3D puzzles, the JollyLook DIY Pinhole Instant Film Camera Kit promises a voyage through time, art, and science. Step into the world of pinhole photography and revel in the joy of creating something truly exceptional.

Conclusion 

JollyLook is a passionate team dedicated to crafting unique experiences that merge creativity, nostalgia, and innovation. With a vision to reconnect individuals with tangible, hands-on pursuits, JollyLook celebrates the beauty of analog photography through its DIY Pinhole Instant Film Camera Kit. 

For more information, use the details below to contact JollyLook. 

Media Contact
Company Name: Jollylook
Contact Person: Customer support
Email: Send Email
Country: United States
Website: https://jollylook.com/

Anti-CD274 (PD-L1) Antibody Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CStone Pharmaceuticals, Celgene, Checkpoint Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Anti-CD274 (PD-L1) Antibody pipeline constitutes key companies continuously working towards developing Anti-CD274 (PD-L1) Antibody treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Anti-CD274 (PD-L1) Antibody Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Anti-CD274 (PD-L1) Antibody Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD274 (PD-L1) Antibody Market.

 

Some of the key takeaways from the Anti-CD274 (PD-L1) Antibody Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Anti-CD274 (PD-L1) Antibody treatment therapies with a considerable amount of success over the years. 
  • Anti-CD274 (PD-L1) Antibody companies working in the treatment market are Curis, Compass Therapeutics, RemeGen, ABL Bio, SystImmune Inc., Incyte Corporation, Biotheus, Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Chia Tai Tianqing Pharmaceuticala, CytomX Therapeutics, Effector Therapeutics, Jubilant Therapeutics, ChemoCentryx, Sorrento Therapeutics, Genor Biopharma, BeiGene, and others, are developing therapies for the Anti-CD274 (PD-L1) Antibody treatment 
  • Emerging Anti-CD274 (PD-L1) Antibody therapies in the different phases of clinical trials are- CA 327, CTX-8371, RC 98, ABL501, GNC-035, INCB086550, PM 8001, Cosibelimab, SHR 1701, TQB 2450, CX-072, Tomivosertib, Research program: programmed cell death 1 ligand 1 inhibitor, CCX 559, Socazolimab, GB226, BGB-A333, and others are expected to have a significant impact on the Anti-CD274 (PD-L1) Antibody market in the coming years.   
  • In August 2022, Chia Tai Tianqing Pharmaceutical Group has commenced a Phase II clinical trial to assess the effectiveness and safety of TQB2450 Injection when combined with chemotherapy with or without Anlotinib Hydrochloride Capsules for the initial treatment of individuals diagnosed with advanced endometrial cancer. Currently, the trial involves 69 participants and is projected to conclude by June 2024.
  • In January 2022, Chia Tai Tianqing Pharmaceutical Group has launched a Phase III clinical trial, which is randomized and open-label, featuring a parallel controlled design. This study aims to compare the effectiveness and safety of TQB2450 when used alongside platinum-containing chemotherapy followed by TQB2450 in combination with Anlotinib against tislelizumab used with platinum-containing chemotherapy followed by tislelizumab in individuals with locally advanced (stage ⅢB/ⅢC), metastatic, or recurrent (Stage IV) non-squamous NSCLC cancer. Currently, the trial involves 390 participants and is expected to conclude by December 2023.

 

Anti-CD274 (PD-L1) Antibody Overview

Programmed death ligand 1 (PD-L1) and its counterpart PD-L2 are surface proteins typically found in normal tissues, serving to regulate T-cell function and prevent autoimmune reactions. In cases of tumors, PD-L1 is frequently overexpressed on the surface of cancer cells. It binds to programmed death 1 (PD-1) found on immune cells within the tumor, leading to a suppression of T-cell activity. This mechanism contributes to immune evasion and is one among several methods employed by tumors to avoid immune system detection and attack.

 

Get a Free Sample PDF Report to know more about Anti-CD274 (PD-L1) Antibody Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight

 

Emerging Anti-CD274 (PD-L1) Antibody Drugs Under Different Phases of Clinical Development Include:

  • CA 327: Curis
  • CTX-8371: Compass Therapeutics
  • RC 98: RemeGen
  • ABL501: ABL Bio
  • GNC-035: SystImmune Inc.
  • INCB086550: Incyte Corporation
  • PM 8001: Biotheus
  • Cosibelimab: Checkpoint Therapeutics
  • SHR 1701: Jiangsu Hengrui Medicine
  • TQB 2450: Chia Tai Tianqing Pharmaceuticala
  • CX-072: CytomX Therapeutics
  • Tomivosertib: Effector Therapeutics
  • Research program: programmed cell death 1 ligand 1 inhibitor: Jubilant Therapeutics
  • CCX 559: ChemoCentryx
  • Socazolimab: Sorrento Therapeutics
  • GB226: Genor Biopharma
  • BGB-A333: BeiGene

 

Anti-CD274 (PD-L1) Antibody Pipeline Therapeutics Assessment

  • Anti-CD274 (PD-L1) Antibody Assessment by Product Type
  • Anti-CD274 (PD-L1) Antibody By Stage and Product Type
  • Anti-CD274 (PD-L1) Antibody Assessment by Route of Administration
  • Anti-CD274 (PD-L1) Antibody By Stage and Route of Administration
  • Anti-CD274 (PD-L1) Antibody Assessment by Molecule Type
  • Anti-CD274 (PD-L1) Antibody by Stage and Molecule Type

 

DelveInsight’s Anti-CD274 (PD-L1) Antibody Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Anti-CD274 (PD-L1) Antibody product details are provided in the report. Download the Anti-CD274 (PD-L1) Antibody pipeline report to learn more about the emerging Anti-CD274 (PD-L1) Antibody therapies

 

Some of the key companies in the Anti-CD274 (PD-L1) Antibody Therapeutics Market include:

Key companies developing therapies for Anti-CD274 (PD-L1) Antibody are – CStone Pharmaceuticals, Celgene, Checkpoint Therapeutics, Alphamab Oncology, Eli Lilly and Company, Novartis Pharmaceuticals, Aurigene Discovery Technologies, Arbutus Biopharma, Compass Therapeutics, Curis, Biotheus, RemeGen, Incyte Corporation, Jubilant Therapeutics, ChemoCentryx, ABL Bio, Chia Tai Tianqing Pharmaceutical, Jiangsu Hengrui Medicine, Sorrento Therapeutics, CytomX Therapeutics, Genmab A/S, Secarna Pharmaceuticals, Avacta Life Sciences Limited, Fate Therapeutics, Hanmi Pharm.Co., Ltd., Celldex Therapeutics, Bolt Biotherapeutics, Bio-Thera Solutions, Acepodia Inc., Janux Therapeutics, Coherus Biosciences, Effector Therapeutics, Palleon Pharmaceuticals, F-star Therapeutics, BeiGene, and others.

 

Anti-CD274 (PD-L1) Antibody Pipeline Analysis:

The Anti-CD274 (PD-L1) Antibody pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Anti-CD274 (PD-L1) Antibody with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anti-CD274 (PD-L1) Antibody Treatment.
  • Anti-CD274 (PD-L1) Antibody key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Anti-CD274 (PD-L1) Antibody Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anti-CD274 (PD-L1) Antibody market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Anti-CD274 (PD-L1) Antibody drugs and therapies

 

Anti-CD274 (PD-L1) Antibody Pipeline Market Drivers

  • Rise in the global prevalence of various cancers, huge investment in the R&D activities, technological advancements and innovations are some of the important factors that are fueling the Anti-CD274 (PD-L1) Antibody Market.

 

Anti-CD274 (PD-L1) Antibody Pipeline Market Barriers

  • However, adverse reactions induced by PD-L1 inhibitors such as immune-related adverse reactions (irAEs) and infusion-related reactions, high development costs can lead to high prices of the drug in the market and other factors are creating obstacles in the Anti-CD274 (PD-L1) Antibody Market growth. 

 

Scope of Anti-CD274 (PD-L1) Antibody Pipeline Drug Insight    

  • Coverage: Global
  • Key Anti-CD274 (PD-L1) Antibody Companies: Curis, Compass Therapeutics, RemeGen, ABL Bio, SystImmune Inc., Incyte Corporation, Biotheus, Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Chia Tai Tianqing Pharmaceuticala, CytomX Therapeutics, Effector Therapeutics, Jubilant Therapeutics, ChemoCentryx, Sorrento Therapeutics, Genor Biopharma, BeiGene, and others
  • Key Anti-CD274 (PD-L1) Antibody Therapies: CA 327, CTX-8371, RC 98, ABL501, GNC-035, INCB086550, PM 8001, Cosibelimab, SHR 1701, TQB 2450, CX-072, Tomivosertib, Research program: programmed cell death 1 ligand 1 inhibitor, CCX 559, Socazolimab, GB226, BGB-A333, and others
  • Anti-CD274 (PD-L1) Antibody Therapeutic Assessment: Anti-CD274 (PD-L1) Antibody current marketed and Anti-CD274 (PD-L1) Antibody emerging therapies
  • Anti-CD274 (PD-L1) Antibody Market Dynamics: Anti-CD274 (PD-L1) Antibody market drivers and Anti-CD274 (PD-L1) Antibody market barriers 

 

Request for Sample PDF Report for Anti-CD274 (PD-L1) Antibody Pipeline Assessment and clinical trials

 

Table of Contents

1. Anti-CD274 (PD-L1) Antibody Report Introduction

2. Anti-CD274 (PD-L1) Antibody Executive Summary

3. Anti-CD274 (PD-L1) Antibody Overview

4. Anti-CD274 (PD-L1) Antibody- Analytical Perspective In-depth Commercial Assessment

5. Anti-CD274 (PD-L1) Antibody Pipeline Therapeutics

6. Anti-CD274 (PD-L1) Antibody Late Stage Products (Phase II/III)

7. Anti-CD274 (PD-L1) Antibody Mid Stage Products (Phase II)

8. Anti-CD274 (PD-L1) Antibody Early Stage Products (Phase I)

9. Anti-CD274 (PD-L1) Antibody Preclinical Stage Products

10. Anti-CD274 (PD-L1) Antibody Therapeutics Assessment

11. Anti-CD274 (PD-L1) Antibody Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Anti-CD274 (PD-L1) Antibody Key Companies

14. Anti-CD274 (PD-L1) Antibody Key Products

15. Anti-CD274 (PD-L1) Antibody Unmet Needs

16 . Anti-CD274 (PD-L1) Antibody Market Drivers and Barriers

17. Anti-CD274 (PD-L1) Antibody Future Perspectives and Conclusion

18. Anti-CD274 (PD-L1) Antibody Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anti-CD274 (PD-L1) Antibody Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CStone Pharmaceuticals, Celgene, Checkpoint Therapeutics

Charting a New Course in Car Accident Law with The Idaho Advocates

“Statistics consistently show that victims who enlist an attorney significantly increase their chances of securing a higher settlement. Our mission is to ensure that every client we represent benefits from hiring our firm, turning a stressful situation into a story of triumph and fair compensation. With The Idaho Advocates, victims are not just getting a lawyer; they’re gaining a powerful ally in their fight for justice and rightful compensation.”
The Idaho Advocates, a leading Boise law firm, champions car accident victims’ rights, offering expert legal support to secure fair compensation. Specializing in auto accident cases, they provide personalized counsel, ensuring victims stand a greater chance of winning higher settlements. Their dedication to client satisfaction and justice makes them a top choice for those affected by car accidents in Boise.

In Boise, Idaho, the frequency of car accidents is on the rise, The Idaho Advocates personal injury law firm stands as a pillar of hope and justice for those affected. Specializing in auto accident cases, this esteemed firm is dedicated to helping victims battle against insurance companies to secure the compensation they deserve.

Understanding the Trauma Behind the Wheel

Car accidents are more than just a collision; they bring a whirlwind of emotional, physical, and financial turmoil. Victims often face daunting medical bills, the cost of vehicle repairs, and the strain of lost wages due to recovery time. The Idaho Advocates deeply understand these challenges and are committed to easing this burden for their clients.

Expertise That Makes a Difference

With an unmatched track record in handling car accident claims, The Idaho Advocates possess the expertise needed to navigate the complexities of personal injury law. Their approach includes a thorough investigation of the accident, gathering of crucial evidence, and meticulous preparation for negotiations or court proceedings. This rigorous process ensures that every client’s case is robustly represented.

The Idaho Advocates are not just representing car accident victims; they are fighting for victims’ rights,” said Branden Huckstep, a leading attorney at The Idaho Advocates. “Statistics consistently show that victims who enlist an attorney significantly increase their chances of securing a higher settlement. Our mission is to ensure that every client we represent benefits from hiring our firm, turning a stressful situation into a story of triumph and fair compensation. With The Idaho Advocates, victims are not just getting a lawyer; they’re gaining a powerful ally in their fight for justice and rightful compensation.”

Client-Centric Approach: Your Advocacy Is Our Priority

The hallmark of The Idaho Advocates’ service is their unwavering dedication to client satisfaction. Recognizing the unique nature of each case, they offer personalized legal counsel, free initial consultations, and continuous support throughout the legal journey. Their aim is to make clients feel heard, respected, and confident in the pursuit of their claims.

Battling Insurance Companies: A Fight for Fairness

Insurance companies, known for their complex procedures and reluctance to offer fair settlements, meet their match in The Idaho Advocates. The firm’s lawyers are adept at understanding and countering these tactics, ensuring that their clients are not short-changed but receive the full compensation they are entitled to.

A Beacon of Legal Expertise in Boise

As Boise continues to grow, so does the likelihood of car accidents. In this evolving landscape, The Idaho Advocates remain a steadfast source of legal expertise and support for car accident victims. Their commitment to securing fair compensation and justice has firmly established them as the leading car accident lawyers in Boise, Idaho.

Contact The Idaho Advocates Today

Victims of car accidents in Boise need not navigate the aftermath alone. The Idaho Advocates are here to help. For more information or to schedule a free consultation, visit idahoadvocates.com or contact them at (208) 995-2444

Media Contact
Company Name: The Idaho Advocates
Contact Person: Damian Kidd
Email: Send Email
Phone: (208) 995-2444
Address:3040 W Elder St.
City: Boise
State: Idaho
Country: United States
Website: https://idahoadvocates.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Charting a New Course in Car Accident Law with The Idaho Advocates

Ecosense Unveils EcoQube Pro™ – A New Concept for Professional Radon Testing

Introducing the NRPP-listed Continuous Radon Monitor for Small and Large-Scale Testing Projects, Enhancing User Efficiency and Cost Savings.

San Jose, CA – December 6, 2023 – Ecosense, a globally trusted provider of cutting-edge radon detection and monitoring solutions, is excited to announce the launch of its professional continuous radon monitor (CRM), the EcoQube Pro™. The EcoQube ProTM has been NRPP-approved, which ensures accuracy and reliability, eliminating the need for confirmation tests. The solution comes as a set of 4 or 45 units and is suitable for use in single-family homes and large-scale projects respectively, such as schools, workplaces, apartment buildings, or care facilities.  It’s truly ideal for versatile radon testing, especially those requiring a 48 to 96-hour deployment period for compliance. Ecosense handles the annual calibration of devices making it a time and cost-saving solution for EcoQube ProTM users.

Ecosense designed the EcoQube ProTM mobile app and web dashboard software with user-friendliness in mind. They have incorporated features that offer significant advantages over traditional methods of radon testing with charcoal canisters. With easy connectivity options, real-time remote monitoring, and autostop capabilities, users will find devices easy to use. The Ecosense cloud server works as a virtual lab ensuring quick access to results data for project management. This software streamlines the integration of test results into inspection reports, offering comprehensive data required for mitigation efforts in properties that surpass the EPA action level of 4 p/Ci. Adopting this new concept eliminates lab feedback delays and the burden of additional mailing fees—truly a transformative breakthrough for the radon industry. 

Insoo Park, the CEO of Ecosense stated, “Ecosense has achieved a revolutionary breakthrough in professional radon detection, forever transforming the radon industry with the introduction of EcoQube ProTM, now certified by NRPP. Our lease program ensures affordability and regulatory compliance, empowering radon professionals in our collective fight against radon dangers.”

The EcoQube ProTM service includes data analysis, annual calibration replacement, and state-required test activity reports. For information about the EcoQube ProTM radon measurement program, please visit the EcoQube ProTM page.

About Ecosense®

Based in the heart of Silicon Valley, Ecosense is a leader in and trusted provider of both professional and consumer radon detection and monitoring solutions that are easy to use, accurate, and fast.  The company’s smart real-time radon detectors utilize a patented radon sensor  technology with high accuracy, delivering reliable results in minutes, not days. The EcoQube was named to TIME’s List of the 100 Best Inventions of 2021 and previously was recognized as a CES 2021 Innovation Awards Honoree in the health and wellness category. November is radon action month, and the Canadian National Radon Proficiency Program (C-NRPP) released a report on the 2023 intercomparison study of continuous radon monitors. The study. featured Ecosense as the industry’s leader in radon detection. 

Media Contact
Company Name: Otter PR
Contact Person: Thomas Mustac
Email: Send Email
Phone: 8136786828
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ecosense Unveils EcoQube Pro™ – A New Concept for Professional Radon Testing

Obesity Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alizyme, Bayer, Bristol-Myers Squibb, Currax Pharmaceuticals, Roche, GSK

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes 100+ key companies continuously working towards developing 130+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Obesity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.

 

Some of the key takeaways from the Obesity Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. 
  • Obesity companies working in the treatment market are D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others, are developing therapies for the Obesity treatment 
  • Emerging Obesity therapies in the different phases of clinical trials are- DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others are expected to have a significant impact on the Obesity market in the coming years.   
  • In June 2023, Comprehensive findings from SURMOUNT-2, a phase 3 clinical trial assessing the effectiveness and safety of Eli Lilly and Company’s tirzepatide (at doses of 10 mg and 15 mg) for managing weight in individuals dealing with obesity or overweight and type 2 diabetes, indicated that tirzepatide resulted in greater weight loss compared to the placebo for both dosage levels. These results were shared at a symposium during the American Diabetes Association’s® (ADA) 83rd Scientific Sessions and were concurrently published in The Lancet.

 

Obesity Overview

Obesity is acknowledged as a chronic or non-communicable ailment, characterized by a multifaceted and intricate nature, affecting individuals primarily due to excessive adiposity or body fat rather than solely body size. This condition can result in metabolic manifestations beyond physical appearance. The undesirable increase in body weight, contributing to obesity and overweight, stands as a primary factor driving the global surge in non-communicable diseases. Consequently, it is categorized as a non-communicable disease.

 

Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/obesity-pipeline-insight

 

Emerging Obesity Drugs Under Different Phases of Clinical Development Include:

  • DD03: D&D Pharmatech
  • AX-0601: ProQR Therapeutics
  • NPM 139: Nano Precision Medical
  • BK-1701: Bukwang Pharmaceutical
  • CBW-520: Caliway Biopharmaceutics
  • YH34160: Yuhan
  • TERN-601: Terns Pharmaceuticals
  • Thermostem: BioRestorative Therapies
  • SCO-267: SCOHIA PHARMA
  • CT-181: Click Therapeutics
  • HM15136: Hanmi Pharmaceuticals
  • NNC0480-0389: Novo Nordisk
  • EMP-16: Empros Pharma
  • CT-868: Carmot Therapeutics
  • Tirzepatide: Eli Lilly and Company
  • Semaglutide: Oral Novo Nordisk

 

Obesity Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Obesity Molecule Type

Obesity Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Obesity Pipeline Therapeutics Assessment

  • Obesity Assessment by Product Type
  • Obesity By Stage and Product Type
  • Obesity Assessment by Route of Administration
  • Obesity By Stage and Route of Administration
  • Obesity Assessment by Molecule Type
  • Obesity by Stage and Molecule Type

 

DelveInsight’s Obesity Report covers around 130+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies

 

Some of the key companies in the Obesity Therapeutics Market include:

Key companies developing therapies for Obesity are – Alizyme, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Takeda Pharmaceuticals, Vivus Inc., Zafgan, Zydus Cadila, and others.

 

Obesity Pipeline Analysis:

The Obesity pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
  • Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Obesity drugs and therapies

 

Obesity Pipeline Market Drivers

  • Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.

 

Obesity Pipeline Market Barriers

  • However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

 

Scope of Obesity Pipeline Drug Insight    

  • Coverage: Global
  • Key Obesity Companies: D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others
  • Key Obesity Therapies: DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others
  • Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
  • Obesity Market Dynamics: Obesity market drivers and Obesity market barriers 

 

Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials

 

Table of Contents

1. Obesity Report Introduction

2. Obesity Executive Summary

3. Obesity Overview

4. Obesity- Analytical Perspective In-depth Commercial Assessment

5. Obesity Pipeline Therapeutics

6. Obesity Late Stage Products (Phase II/III)

7. Obesity Mid Stage Products (Phase II)

8. Obesity Early Stage Products (Phase I)

9. Obesity Preclinical Stage Products

10. Obesity Therapeutics Assessment

11. Obesity Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Obesity Key Companies

14. Obesity Key Products

15. Obesity Unmet Needs

16 . Obesity Market Drivers and Barriers

17. Obesity Future Perspectives and Conclusion

18. Obesity Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alizyme, Bayer, Bristol-Myers Squibb, Currax Pharmaceuticals, Roche, GSK

Greg’s Deadly Draft is a new Mascot Horror Game that takes place in a football stadium, and it’s amazing

“Greg’s Deadly Draft, a mascot horror game.”

Silvercity Sharks just released a new horror mascot game called Greg’s Deadly Draft, featuring a real shark mascot called Greg. Play against Greg White Shark in a battle for your life as he tries to recruit you for his failing football team. Greg is putting you through several trials to see if you would make a good fit on his roster. Will you survive?

Dropped by your adversaries is a potion that gives you an advantage in combat and stealth. Try to get around greg’s deadly traps in order to escape his football field horror! Make your way to the depths of the stadium and find the clues to get your way out!

Greg’s Deadly Draft is a Single-player horror mascot game where you have to complete a set of challenges by the deadly mascot, evade traps and complete puzzles in order to continue. The players are tasked with doing challenges such as throwing your football at targets, collect serums and much more. You will also be chased around the map, while you can always throw footballs at the enemies head as you will be equipped with unlimited number of footballs which you can throw at targets, alongside of others such as the anchor – which will stop enemies dead on their tracks for a limited time only.

Watch the official trailer below: https://www.youtube.com/watch?v=Ksfw8mDa4ms&ab_channel=SilvercitySharks.

Will you be checking it out and get into Greg’s deadly draft? You can try out the game right now on STEAM here available for only $4.99.

Media Contact
Company Name: Indielush
Contact Person: Gerardo
Email: Send Email
Country: United Kingdom
Website: http://Indielush.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Greg’s Deadly Draft is a new Mascot Horror Game that takes place in a football stadium, and it’s amazing

Minibus Hire London Revolutionizes Group Travel with Premier, Customizable Services for Diverse Clientele

Offering an Unmatched Array of Services, Minibus Hire London Promises Safe, Comfortable, and Efficient Transportation Across the UK Capital for All Types of Events and Occasions

Minibus Hire London, an esteemed name in the transport sector, has proudly announced its exceptional minibus rental services, catering to a wide range of clients in London and beyond. This announcement marks a significant enhancement in group travel, offering a diverse fleet capable of accommodating 6 to 72 passengers, thus meeting the varying needs of both local and international clientele. 

The company’s commitment to safety is evident, with all drivers being CRB checked, ensuring a secure travel experience for passengers. This emphasis on safety is coupled with the versatility of the fleet, which includes vehicles for all occasions, be it airport transfers, sports events, weddings, funerals, school trips, tours, or excursions. Minibus Hire London stands out with its nationwide coverage, extending its services across all areas. 

A key feature of Minibus Hire London is the provision of a comfortable, secure, and dedicated transport solution. The minibuses are designed to offer comfort and luxury, boasting a fleet in excellent condition, ensuring a top-notch travel experience. The company understands the nuances of navigating London, a city that can present challenges such as crowded public transport and traffic congestion. To counter this, Minibus Hire London offers a seamless, stress-free travel solution, redefining the experience of exploring the city.

In addition to comfort, Minibus Hire London prides itself on its versatility. The company offers options for self-drive minibuses, catering to those who prefer to take the wheel themselves. For those seeking a more relaxed experience, professional chauffeurs with extensive knowledge of London are available, offering a journey in safety and luxury. The company’s fleet is equipped with modern amenities such as climate control, Wi-Fi, and ample luggage space, ensuring a comfortable journey regardless of the destination. 

Recognizing the importance of punctuality, especially for airport transfers, Minibus Hire London provides reliable services to major airports in London, including Heathrow, Gatwick, Stansted, Luton, and London City Airport. The company’s efficient booking service and commitment to customer satisfaction are evident in its flexible pick-up and drop-off arrangements, devoid of hidden fees for waiting or stopping.

Children’s safety and entertainment during travel are given special attention. The larger coaches in the fleet are equipped with amenities like TV monitors, climate control, and toilets, making them ideal for school trips and family outings. The coaches’ multiple stop capability ensures a convenient and safe travel experience for all occasions.

Minibus Hire London caters to a wide array of events, including weddings, family functions, corporate events, and more, offering customizable services to suit the specific needs of each client. The company’s commitment to affordability, coupled with state-of-the-art GPS systems in their vehicles, ensures an efficient, cost-effective travel solution.

With years of experience in the transport field, Minibus Hire London has established itself as a leader in providing premier minibus hire services. The company’s collaboration with other service providers enhances the overall group trip experience, making it a reliable choice for transport needs in London. 

Concluding this announcement, Minibus Hire London reaffirms its dedication to offering high-quality, affordable transport solutions, ensuring a memorable and comfortable travel experience for all clients. 

For more information, and to have glimpse of their offerings kindly visit the official website.

Media Contact
Company Name: Minibus Hire London
Contact Person: David Miller
Email: Send Email
Country: United Kingdom
Website: https://www.minibushirelondon.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Minibus Hire London Revolutionizes Group Travel with Premier, Customizable Services for Diverse Clientele

Revolutionizing Healthcare Efficiency with VMeDx’s Expert Virtual Medical Assistants for All US Medical Professionals

Explore the Exceptional Benefits of Integrating VMeDx’s Advanced Virtual Assistance into Medical Practices for Enhanced Patient Care and Streamlined Administrative Processes

VMeDx emerges as a pioneering force in the healthcare sector, offering unparalleled virtual medical assistant services tailored to the unique needs of US healthcare professionals, including medical doctors, veterinarians, and dentists. This company is redefining the healthcare space by integrating state-of-the-art virtual assistance into daily medical operations.

At the core of VMeDx’s offerings lies the adaptation to digital practices in healthcare. Recognizing the digital shift in the healthcare sector, VMeDx provides virtual medical assistants adept at navigating the digital economy. These assistants are not just administrative aides but pivotal in enhancing patient care and practice efficiency. They bring many services, including email management, answering phone calls, calendar arrangements, prior authorizations, insurance verification, referrals, credentialing, scribing, and more. This comprehensive approach ensures that healthcare professionals can focus on their primary patient care tasks while VMeDx takes care of the rest.

Central to VMeDx’s core mission is providing customized assistance and continuous support. Each virtual assistant is HIPAA trained and certified and meticulously matched to any medical organization’s specific needs, complimented by dedicated account managers. This bespoke service ensures seamless integration and ongoing support, optimizing medical practice operations.

VMeDx’s commitment to training and compliance is another cornerstone of their service. The company employs a rigorous training process, enabling virtual assistants to leverage and utilize state-of-the-art tools, software, and our in-house CRM while ensuring adherence to strict security practices and quality assurance protocols. 

Medicine and healthcare are constantly evolving in the medical industry, and VMeDx stands out for its adaptability and commitment to continuous improvement and adaptation. The company ensures that its virtual assistants and account managers remain abreast of the latest developments in healthcare, thereby bringing efficiency and innovation to our clients. 

The long-term benefits of partnering with VMeDx are substantial. Practices that engage with VMeDx report streamlined operations, improved security, and enhanced quality, all contributing to increased revenue and heightened patient satisfaction. This transformative approach is about providing virtual assistance and elevating the entire medical practice to its full potential. 

VMeDx is not merely a staffing company but an organization whose core values revolve around uplifting lives and supporting local healthcare causes like the Philippine Cancer Society.

For more information about VMeDx and their transformative services, visit https://vmedx.com/ or contact Vladimir Gasic via email at info@vmedx.com.

Media Contact
Company Name: VMeDx
Contact Person: Vladimir Gasic
Email: Send Email
Phone: +1 615 569 1053
Country: United States
Website: https://vmedx.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Revolutionizing Healthcare Efficiency with VMeDx\’s Expert Virtual Medical Assistants for All US Medical Professionals

Prime Dumpster Incorporated Unveils Premier Porta Potty Rentals for Los Angeles, Setting a New Standard in Convenience and Hygiene

Prime Dumpster Incorporated is a leading waste management facilitation service committed to enhancing sanitation and waste management solutions. With a strong focus on hygiene, convenience, and customer satisfaction, Prime Dumpster Incorporated offers a wide range of waste management solutions, including premium porta potty rentals, roll-off dumpster rentals, and residential and commercial waste services.

Prime Dumpster Incorporated, a leading waste management facilitation service, is delighted to announce its premium porta potty rental services, designed to meet the diverse needs of Los Angeles residents, event organizers, and construction sites. With a strong commitment to hygiene, convenience, and customer satisfaction, Prime Dumpster Incorporated is poised to set a new benchmark for porta potty rentals in the vibrant city of Los Angeles.

Los Angeles, known for its diverse events and bustling construction industry, demands top-notch portable sanitation solutions. Prime Dumpster Incorporated recognizes this need and is dedicated to providing high-quality, clean, and accessible porta potties for a variety of applications.

Prime Dumpster Incorporated’s spokesperson stated: “Our porta potty rental services in Los Angeles are a testament to our commitment to meeting the unique needs of our clients. We understand that convenient and hygienic restroom facilities are essential for events and construction sites alike. Prime Dumpster Incorporated is proud to offer top-tier porta potties that not only meet but exceed our customers’ expectations.”

Prime Dumpster Incorporated’s porta potty rental services bring numerous advantages to clients in Los Angeles:

  1. Diverse Solutions: From upscale events to construction sites, Prime Dumpster Incorporated offers a range of porta potty options to suit various needs. They offer standard, deluxe, ADA-compliant, luxury restroom trailers, and more.

  2. Exceptional Hygiene: Hygiene is paramount, and Prime Dumpster Incorporated ensures that all porta potties are meticulously cleaned, sanitized, and well-maintained before delivery.

  3. Accessibility: The company offers ADA-compliant porta potties to ensure that all guests, including those with disabilities, can access restroom facilities comfortably.

  4. Prompt Delivery and Pickup: Prime Dumpster Incorporated is committed to punctuality, guaranteeing on-time delivery and pickup of porta potties, allowing clients to focus on their events or projects.

A satisfied event organizer shared her experience: “Planning large-scale events in Los Angeles can be challenging, but Prime Dumpster Incorporated’s porta potty rentals made the logistics so much easier. Their clean and well-maintained units impressed both our guests and our team. We’re grateful for their contribution to our event’s success.”

Prime Dumpster Incorporated’s porta potty rental services are available throughout Los Angeles and the surrounding areas, providing portable sanitation solutions for events, construction sites, and any location in need of reliable restroom facilities.

Clients can easily request a quote, schedule porta potty deliveries and pickups, and access customer support through Prime Dumpster Incorporated’s user-friendly online platform. The company’s dedicated team of experts is always available to assist in selecting the right porta potty options and service plans to match each client’s specific requirements.

In addition to porta potty rentals, Prime Dumpster Incorporated offers a comprehensive suite of waste management solutions, including roll-off dumpster rentals, and residential and commercial waste services.

For more information about Prime Dumpster Incorporated and their porta potty rental services in Los Angeles, please visit Prime Dumpster porta potty rentals in Los Angeles, CA, or contact +1 (844) 853-3867.

Prime Dumpster Incorporated invites Los Angeles residents, event organizers, and construction professionals to experience the convenience and hygiene of their porta potty rentals. Elevate your sanitation standards with Prime Dumpster Incorporated.

Media Contact
Company Name: Prime Dumpster Incorporated
Contact Person: Ron
Email: Send Email
Phone: +1 (844) 853-3867
Address:12172 South Route 47 Unit 109
City: Huntley
State: IL
Country: United States
Website: https://primedumpster.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prime Dumpster Incorporated Unveils Premier Porta Potty Rentals for Los Angeles, Setting a New Standard in Convenience and Hygiene

New novel “The Dragonfly Prophecy” by Jacquelyn Castle is released, a young adult fantasy about a young woman’s struggles with love, death, and coming to terms with destiny

“The Dragonfly Prophecy” by Jacquelyn Castle has been released worldwide. This 249-page young adult fantasy novel follows Lexi Blane, a seventeen-year-old with a seemingly perfect life and a bright, predictable future. Despite outward appearances, Lexi is frustrated, feels overprotected, and suffers from a mysterious illness that only seems to be getting worse. On a tropical vacation with her parents and too-good-to-be-true boyfriend, her condition takes a turn for the worse, and the life she thought she knew begins to unravel in shocking ways.

As the story progresses, the line between dreams and reality blurs for Lexi, and she finds herself struggling to make sense of the barrage of conflicting, confusing experiences. Soon she begins to understand that a picturesque life isn’t at all what fate has in store for her.

Written with descriptive, sometimes snarky language that’s perfect for engaging teen readers, Castle’s novel brings issues of identity and uncertainty about the future into a fantasy world that reflects the confusion of growing up. Inspired by events in her own life, the author grounds the story with dynamic characters, vivid emotion, and Lexi’s relatable inner thoughts.

Throughout the novel, readers are reminded that love is a powerful force that transcends boundaries, even space and time, and that instincts are a gift that shouldn’t be ignored. As a coming of age story, Lexi must also recognize that despite her intellect, she still has plenty to learn.

Adventurous, romantic, funny, and wonderfully compelling, Jacquelyn Castle has created a brilliant YA novel that brings readers on an exciting journey through parallel worlds and unexpected twists, and teaches important life lessons along the way.

The Dragonfly Prophecy (ISBN: 9781961532670) can be purchased through retailers worldwide, including Barnes and Noble and Amazon. The paperback retails for $16.99 and the ebook retails for $4.99. Review copies and interviews are available upon request.

From the back cover:

It has been said that dragonflies are symbolic of imminent change:

~ Dreaming of one signifies that life is not what it appears to be
~ Dreaming of a swarm denotes dark stains of guilt on the soul.
~ Dreaming of ingesting one means that one is devoured with a passion that needs to break free to the surface.

I ignored the dragonflies that haunted my dreams.

Seventeen-year-old Lexi Blane believed she was the creator of her own destiny. With a brilliant mind, a flawless boyfriend, and parents who would stop the earth from spinning for her, all was going according to plan.

But when her perfect world unravels into one she doesn’t know, it reveals the painful truth of her love, trust, and entire being. In the struggle to find her true self, Lexi learns she didn’t create her destiny – it created her.

About the author:

A native New Yorker, and still a frequent visitor, Jacquelyn currently lives in New Jersey with her three children and their Pug named Frank. She graduated Mount Sant Mary College with an accounting degree and embarked on a career in finance. Always passionate about writing magical stories since she was a teen, she continued writing in her spare time. With dozens of unfinished manuscripts on her computer, Jacquelyn decided to finally pursue her life-long dream of sharing her stories and taking readers to fantastic places.

Jacquelyn’s connection to the characters in her debut novel, The Dragonfly Prophecy, ran deep and the story had been on her mind since she typed the first word years ago. Keep an eye out for all of Jacquelyn’s novels as she finishes each one, all with memorable characters who navigate their way through the twists and turns of life and love.

About MindStir Media:

MindStir Media LLC is an award-winning book publisher. To learn more about publishing a book with MindStir Media, visit http://mindstirmedia.com or call 800-767-0531.

 

Media Contact
Company Name: MindStir Media LLC
Contact Person: Jen McNabney
Email: Send Email
Phone: 800-767-0531
Address:1 New Hampshire Ave Suite 125
City: Portsmouth
State: NH
Country: United States
Website: https://mindstirmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New novel \”The Dragonfly Prophecy\” by Jacquelyn Castle is released, a young adult fantasy about a young woman’s struggles with love, death, and coming to terms with destiny